Gotham Asset Management LLC Purchases 138,812 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Gotham Asset Management LLC lifted its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 41.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 477,768 shares of the company's stock after buying an additional 138,812 shares during the period. Gotham Asset Management LLC owned about 0.10% of Elanco Animal Health worth $5,786,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of ELAN. CoreCap Advisors LLC bought a new stake in shares of Elanco Animal Health in the 4th quarter valued at about $29,000. Jones Financial Companies Lllp raised its stake in Elanco Animal Health by 95.6% in the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after buying an additional 2,059 shares during the period. SRS Capital Advisors Inc. lifted its position in shares of Elanco Animal Health by 221.2% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock valued at $60,000 after buying an additional 3,411 shares during the last quarter. MRP Capital Investments LLC bought a new position in shares of Elanco Animal Health during the 4th quarter worth approximately $61,000. Finally, Blue Trust Inc. boosted its stake in shares of Elanco Animal Health by 47.7% during the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after acquiring an additional 1,894 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Insider Activity

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the company's stock in a transaction on Tuesday, March 11th. The shares were purchased at an average cost of $10.20 per share, with a total value of $102,000.00. Following the completion of the purchase, the director now owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. This represents a 9.86% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.89% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ELAN. Morgan Stanley cut their price target on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus lifted their target price on shares of Elanco Animal Health from $15.00 to $16.00 and gave the stock a "buy" rating in a report on Monday. UBS Group lowered their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Piper Sandler reduced their price objective on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, March 6th. Finally, Barclays dropped their price target on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, Elanco Animal Health has an average rating of "Hold" and an average target price of $15.17.

Elanco Animal Health Trading Up 1.6%

NYSE ELAN traded up $0.20 during mid-day trading on Monday, reaching $13.12. 1,553,467 shares of the stock were exchanged, compared to its average volume of 5,029,820. The stock has a market cap of $6.52 billion, a P/E ratio of 32.79, a P/E/G ratio of 2.50 and a beta of 1.49. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $18.80. The stock has a 50 day simple moving average of $10.11 and a 200-day simple moving average of $11.43.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.06. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period in the previous year, the firm earned $0.34 earnings per share. The company's revenue was down 1.0% compared to the same quarter last year. On average, analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.